Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07265739 · ClinicalTrials.gov registry record · Phase 2
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT07265739: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT07265739 is a Phase 2 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 27 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07265739, a Phase 2 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this Phase II study is to measure the effects of a combination of study drugs, losartan and paclitaxel, on platinum resistant ovarian cancer.
Primary Outcome
ORR will be determined as the number of patients with a partial response (PR) or complete response (CR) to therapy by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
Interventions
- DRUG Paclitaxel
- DRUG losartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2026-08 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 2 |
What is known before NCT07265739 opens enrollment
NCT07265739 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT07265739 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07265739 about?
NCT07265739 is a clinical study titled "Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer". The purpose of this Phase II study is to measure the effects of a combination of study drugs, losartan and paclitaxel, on platinum resistant ovarian cancer.
What is the current status of trial NCT07265739?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2026-08. Estimated completion is 2028-12-30.
What interventions are being tested in trial NCT07265739?
The interventions under investigation include: Paclitaxel (DRUG), losartan (DRUG).
Who is sponsoring clinical trial NCT07265739?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07265739's enrollment target sits among peer trials
27 1697th of 2000 higher than 293 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia